Dr. Wendy Wobeser works as a clinician scientist in the Department of Infection & Immunology at the Hotel Dieu Hospital in Kingston, Ontario, and as an associate professor of medicine at Queen’s University, also in Kingston.
She completed a Master of Science in epidemiology at the University of Toronto and a medical degree at the University of Saskatchewan. She split her undergraduate studies between Carleton University and the University of Saskatchewan College of Medicine. She works as a clinician-scientist, allowing her to facilitate the involvement of the affected community in shaping the scientific agenda and supporting advances in the medical field.
Dr. Wobeser is an internationally recognized leader in the field of tuberculosis. She holds important positions on the Tuberculosis Section Executive of the International Union Against Tuberculosis and Lung Disease and the Canadian Tuberculosis Committee, and is recognized as a senior HIV clinical expert with particular interest in treatment for the incarcerated.
She has been a co-investigator for several CTN studies, including CTN 286: TriiAdd Study, which aims to evaluate the effect on ART adherence and virologic control of HIV of the switch from traditional antiretroviral therapies to Triumeq, a new single tablet anti-HIV treatment. Other studies she is involved in include CTN 247, which looks at disease progression in long term HIV-positive individuals, CTN 254, which aims to determine whether inflammatory markers can predict HIV disease progression in persons who have not started ART, and CTN 238, which studied micronutrient supplementation in people living with HIV who had not yet been treated.
